COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 2 FDA records to the applicant name Cerapedics, LLC. It includes 1 original PMA approval. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Nov 3, 2015 to Sep 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NOX appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P140019, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 11025 Dover St., Suite 1600, Westminster, CO, 80021. Recorded on P140019/S014, decision dated Sep 16, 2026.
Device categories in this collection
Filler, Bone Void, Synthetic Peptide.
Changes described in PMA records
The supplied record describes P140019/S014, a 30-Day Notice for Cerapedics, LLC under product code NOX, device category 'Filler, bone void, synthetic peptide.' The notice states changes to P-15 manufacturing at Bachem Americas attributed to 'equipment technological advancements and to improve process efficiency,' plus a series of minor or administrative specification changes. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier.
The identifier ties this filing to the existing P140019 PMA as a supplement, not a new approval of the whole system. The source gives no details on which specifications changed, what equipment was involved, or what validation supported the change. The stated purpose of improving process efficiency is the applicant's description of intent and does not by itself establish safety or clinical effectiveness.
Readers should note what is absent: the record does not describe the original P-15 scope, the peptide's role, or any performance data. Regulatory status here is procedural, and the decision code 'OK30' appears without further explanation in the supplied fields.
FDA approval-order wording
changes to the P-15 manufacturing occurring at Bachem Americas due to equipment technological advancements and to improve process efficiency , as well as a series of minor/administrative specifications changes
Sep 16, 2026 · 30-Day NoticeFDA’s recorded scope: APPROVAL FOR THE I-FACTOR PEPTIDE ENHANCED BONE GRAFT. THIS COMBINATION PRODUCT IS INDICATED FOR USE IN SKELETALLY MATURE PATIENTS FOR RECONSTRUCTION OF A DEGENERATED CERVICAL DISC AT ONE LEVEL FROM C3-C4 TO C6-C7 FOLLOWING SINGLE-LEVEL DISCECTOMY FOR INTRACTABLE RADICULOPATHY (ARM PAIN AND/OR A NEUROLOGICAL DEFICIT), WITH OR WITHOUT NECK PAIN, OR MYELOPATHY DUE TO A SINGLE-LEVEL ABNORMALITY LOCALIZED TO THE DISC SPACE, AND CORRESPONDING TO AT LEAST ONE OF THE FOLLOWING CONDITIONS CONFIRMED BY RADIOGRAPHIC IMAGING (CT, MRI, X-RAYS): HERNIATED NUCLEUS PULPOSUS, SPONDYLOSIS (DEFINED BY THE PRESENCE OF OSTEOPHYTES), AND/OR VISIBLE LOSS OF DISC HEIGHT AS COMPARED TO ADJACENT LEVELS, AFTER FAILURE OF AT LEAST 6 WEEKS OF CONSERVATIVE TREATMENT. I-FACTOR PEPTIDE ENHANCED BONE GRAFT P-15 PUTTY MUST BE USED INSIDE AN ALLOGRAFT BONE RING AND WITH SUPPLEMENTAL ANTERIOR PLATE FIXATION.
Nov 3, 2015Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.